VISENTIN, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 716
EU - Europa 164
AS - Asia 44
AF - Africa 4
SA - Sud America 2
Totale 930
Nazione #
US - Stati Uniti d'America 710
IT - Italia 62
FR - Francia 42
CN - Cina 28
DE - Germania 22
IN - India 10
CZ - Repubblica Ceca 8
CA - Canada 6
FI - Finlandia 5
RU - Federazione Russa 5
ZA - Sudafrica 4
IE - Irlanda 3
NL - Olanda 3
SE - Svezia 3
UA - Ucraina 3
DK - Danimarca 2
GB - Regno Unito 2
LT - Lituania 2
BR - Brasile 1
CL - Cile 1
GR - Grecia 1
HK - Hong Kong 1
ID - Indonesia 1
IL - Israele 1
JP - Giappone 1
KH - Cambogia 1
LV - Lettonia 1
SA - Arabia Saudita 1
Totale 930
Città #
Fairfield 90
Ashburn 58
Houston 58
Seattle 54
Santa Cruz 44
Woodbridge 44
Padova 43
Cambridge 37
Buffalo 35
Wilmington 25
Ann Arbor 21
Des Moines 17
Chicago 16
New York 10
San Diego 10
Beijing 8
Paris 8
Boardman 7
San Francisco 6
Helsinki 5
Las Vegas 5
Shanghai 5
Chennai 4
Lake Forest 4
Los Angeles 4
Phoenix 4
Ulm 4
Belluno 3
Bengaluru 3
Dublin 3
Easton 3
Henderson 3
Milan 3
Muizenberg 3
Ottawa 3
San Jose 3
University Park 3
Brendola 2
Clearwater 2
Dallas 2
Denver 2
Frankfurt am Main 2
Hangzhou 2
Jacksonville 2
Longarone 2
Madison 2
Mumbai 2
Saint Petersburg 2
Trieste 2
Uppsala 2
Verona 2
Amsterdam 1
Atlanta 1
Baltimore 1
Boulder 1
Büdelsdorf 1
Caprino Veronese 1
Cedar Knolls 1
Condat-sur-Vienne 1
Copenhagen 1
Crugers 1
Hamilton 1
Herndon 1
Hillsboro 1
Hong Kong 1
Honolulu 1
Jakarta 1
Kakinada 1
Lombard 1
Miami 1
Moscow 1
Nashville 1
Nuremberg 1
Nürnberg 1
Pavilion 1
Phnom Penh 1
Pozzo della Chiana 1
Provo 1
Recife 1
Riva 1
Rome 1
Salaspils 1
Santa Clara 1
Scottsdale 1
Silverton 1
Tel Aviv 1
Thumeries 1
Tianjin 1
Toronto 1
Trecastagni 1
Umeda 1
Washington 1
Wuhan 1
Yellow Springs 1
Totale 727
Nome #
Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals, file e14fb26a-115f-3de1-e053-1705fe0ac030 173
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases, file e14fb26a-54a7-3de1-e053-1705fe0ac030 135
Role of miR-15a/miR-16-1 and TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia, file e14fb26a-0d5c-3de1-e053-1705fe0ac030 131
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival, file e14fb268-c45b-3de1-e053-1705fe0ac030 125
In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment, file e14fb26c-b00a-3de1-e053-1705fe0ac030 81
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact, file e14fb26f-8462-3de1-e053-1705fe0ac030 54
Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells, file e14fb26a-2040-3de1-e053-1705fe0ac030 49
p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape, file e14fb26c-aa0d-3de1-e053-1705fe0ac030 47
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia, file e14fb26f-c351-3de1-e053-1705fe0ac030 17
Expression and function of protein kinase CK2 in Hodgkin lymphoma, file e14fb26f-ace7-3de1-e053-1705fe0ac030 13
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation, file aaf97301-4e55-41ac-9882-55c2bbada3e2 12
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL), file 84a7338a-70b8-4567-a75e-9fa4b34371ef 10
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases, file 9b3cbfb3-3721-4aff-b62c-9881031ace9e 10
[18F]FDG PET/CT and PET/MR in Patients with Adrenal Lymphoma: A Systematic Review of Literature and a Collection of Cases, file be7c8f1f-c156-4a8a-8270-408e14a71f5c 10
Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients., file ccb0f900-3a13-424d-b6a4-e86c01bf471a 10
Incidental lymphomas in surgical pathology: diagnostic clues and clinical-pathological correlations, file c6955adf-1a8b-4b31-9e94-81141158156e 9
Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients., file e14fb269-5ca4-3de1-e053-1705fe0ac030 9
Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies, file e14fb26e-7bdd-3de1-e053-1705fe0ac030 9
Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma, file e14fb26f-94c8-3de1-e053-1705fe0ac030 9
Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment, file 740b5ad3-ee0f-49ee-85f6-dccc0c3de70c 7
Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia, file e14fb268-fa8e-3de1-e053-1705fe0ac030 7
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab, file e14fb26d-56a7-3de1-e053-1705fe0ac030 7
Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins, file e14fb268-9d8a-3de1-e053-1705fe0ac030 6
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic Leukemia. A Real‐Life Campus CLL Study, file 1d074405-2d70-4d33-a979-caf9a5b10ef5 5
Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort, file 946beae7-7b7c-43bb-9fa5-74ef660fbe05 5
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome, file d7e4eb92-287a-4ae3-b665-be3507ac63fa 4
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL, file e14fb26f-dde3-3de1-e053-1705fe0ac030 4
A Case of Hemophagocytic Lymphohistiocytosis Triggered by Disseminated Tuberculosis and Hairy Cell Leukaemia after SARS-CoV2 Infection, file cc5f4ec7-9e9b-4eb1-b070-c9ae9bf08256 3
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia, file 0b3369ba-1329-4135-9e52-6b1c523f2fb4 2
Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia, file e14fb270-0143-3de1-e053-1705fe0ac030 2
Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia, file e14fb268-fb50-3de1-e053-1705fe0ac030 1
Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-MAG antibody polyneuropathy, file e14fb26e-73ce-3de1-e053-1705fe0ac030 1
Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL, file e14fb26f-238a-3de1-e053-1705fe0ac030 1
Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature, file e14fb26f-dde8-3de1-e053-1705fe0ac030 1
Totale 969
Categoria #
all - tutte 3.383
article - articoli 3.257
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.640


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201970 0 0 0 0 0 0 0 1 5 15 26 23
2019/2020118 15 8 7 9 12 10 8 11 13 6 13 6
2020/2021157 11 9 10 6 4 7 7 18 22 34 21 8
2021/2022248 8 14 24 18 28 13 13 21 4 12 71 22
2022/2023247 16 19 52 37 19 28 10 9 6 8 38 5
2023/2024106 8 7 10 5 9 28 23 16 0 0 0 0
Totale 969